Table Graph
      published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOLCORONA, 2021 0.56 [0.19; 1.66] 0.56[0.19; 1.66]COLCORONA, 202110%4,488NAnot evaluable hospitalization or deathdetailed resultsCOLCORONA, 2021 0.79 [0.61; 1.03] 0.79[0.61; 1.03]COLCORONA, 202110%4,488NAnot evaluable hospitalizationdetailed resultsCOLCORONA, 2021 0.79 [0.60; 1.04] 0.79[0.60; 1.04]COLCORONA, 202110%4,488NAnot evaluable mechanical ventilationdetailed resultsCOLCORONA, 2021 0.53 [0.25; 1.11] 0.53[0.25; 1.11]COLCORONA, 202110%4,488NAnot evaluable related AE (TRAE)detailed resultsCOLCORONA, 2021 1.74 [1.50; 2.03] 1.74[1.50; 2.03]COLCORONA, 202110%4,412NAnot evaluable serious adverse eventsdetailed resultsCOLCORONA, 2021 0.77 [0.60; 1.00] 0.77[0.60; 1.00]COLCORONA, 202110%4,412NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-01 07:50 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons